[사회][현장영상] Ministry of Food and Drug Safety “approved for Pfizer special import ‘117,000 times'”

[앵커]

In connection with the introduction of 60,000 Pfizer vaccines secured through the vaccine joint purchase project’CoVax Facility’, the Ministry of Food and Drug Safety approved a special import for a while.

Let’s listen.

[김강립 / 중앙재난안전대책본부 총괄대변인]

This is Kang-Rip Kim, Director of the Ministry of Food and Drug Safety. Pfizer’s Vaccine Cominati, which is expected to be supplied, was approved today. This special income was made at the request of the Korea Disease Administration through a joint expert advisory meeting with the Ministry of Food and Drug Safety and the Korea Disease Control Agency.

The approved amount for special import is 117,000 times and will be imported into Korea from mid-February through the Korea Rare Essential Medicine Center once the detailed supply schedule is confirmed by KOVAX.

Vaccines approved today are limited to the amount of vaccines that will be supplied directly to Korea in accordance with the contract between the Korea Disease Administration and COVAX, and are different from vaccines to be imported through Pfizer Korea.

Gabi, the World Association for Vaccine Immunization, announced that it will distribute and supply about 1 million doses of Covax Pfizer vaccine as the primary supply to 6 to 12 countries earlier this year, and to complete procedures such as special approval within the country where the vaccine is to be introduced. As it was presented as a prerequisite for supply, the special import procedure was quickly promoted.

The Ministry of Food and Drug Safety and the Korea Disease Administration held a joint expert advisory meeting on February 2 to receive advice from experts on safety, effectiveness and the need for special imports.

The joint expert advisory meeting includes one expert recommended by the Korean Medical Association, such as an infectious medicine specialist and a vaccine virology specialist, such as the KFDA’s COVID-19 treatment vaccine safety and effectiveness verification advisory group and the Korea Disease Administration’s COVID-19 expert advisory group. It consisted of 11 people in total.

Pfizer’s Corona 19 vaccine, which will be introduced and inoculated for the first time in Korea through COVAX, is the first vaccine developed using the mRNA vaccine platform.

This vaccine is the first vaccine to be listed on the emergency use list by the World Health Organization, and it has been approved for emergency use or conditionally licensed by 28 regulatory agencies around the world, including the United States, the European Union, and the United Kingdom. Vaccination is already being done in several countries, including Singapore and Israel. Clinical trial data submitted at the time of preliminary review…

※’Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]